157 related articles for article (PubMed ID: 30931862)
1. Protein-Protein Interactions of Phosphodiesterases.
Al-Nema MY; Gaurav A
Curr Top Med Chem; 2019; 19(7):555-564. PubMed ID: 30931862
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide specific phosphodiesterases of Leishmania major.
Johner A; Kunz S; Linder M; Shakur Y; Seebeck T
BMC Microbiol; 2006 Mar; 6():25. PubMed ID: 16522215
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5.
Schankin CJ; Kruse LS; Reinisch VM; Jungmann S; Kristensen JC; Grau S; Ferrari U; Sinicina I; Goldbrunner R; Straube A; Kruuse C
Headache; 2010 Mar; 50(3):431-41. PubMed ID: 19751368
[TBL] [Abstract][Full Text] [Related]
4. Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry.
Reinecke D; Schwede F; Genieser HG; Seifert R
PLoS One; 2013; 8(1):e54158. PubMed ID: 23342095
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
6. Advances, Perspectives and Potential Engineering Strategies of Light-Gated Phosphodiesterases for Optogenetic Applications.
Tian Y; Yang S; Gao S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066112
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.
Andrés JI; De Angelis M; Alcázar J; Celen S; Bormans G
Curr Top Med Chem; 2012; 12(11):1224-36. PubMed ID: 22571785
[TBL] [Abstract][Full Text] [Related]
9. The role of phosphodiesterases in schizophrenia : therapeutic implications.
Siuciak JA
CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterases in the central nervous system.
Kleppisch T
Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
[TBL] [Abstract][Full Text] [Related]
11. Channeling of cAMP in PDE-PKA Complexes Promotes Signal Adaptation.
Tulsian NK; Krishnamurthy S; Anand GS
Biophys J; 2017 Jun; 112(12):2552-2566. PubMed ID: 28636912
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.
Cheepala S; Hulot JS; Morgan JA; Sassi Y; Zhang W; Naren AP; Schuetz JD
Annu Rev Pharmacol Toxicol; 2013; 53():231-53. PubMed ID: 23072381
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
Andersson KE; Uckert S; Stief C; Hedlund P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Preedy MEJ
Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of cyclic nucleotide hydrolysis in the phosphodiesterase catalytic site.
Salter EA; Wierzbicki A
J Phys Chem B; 2007 May; 111(17):4547-52. PubMed ID: 17425352
[TBL] [Abstract][Full Text] [Related]
17. Structural and biochemical characterization of the catalytic domains of GdpP reveals a unified hydrolysis mechanism for the DHH/DHHA1 phosphodiesterase.
Wang F; He Q; Su K; Wei T; Xu S; Gu L
Biochem J; 2018 Jan; 475(1):191-205. PubMed ID: 29203646
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q; Wang Y; Yan C; Xiang YK
Physiol Rev; 2024 Apr; 104(2):765-834. PubMed ID: 37971403
[TBL] [Abstract][Full Text] [Related]
20. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
